PDCD1 and melanoma: Previous studies demonstrated that reprogramming the immunosuppressive capacity of MDSCs or inhibiting its biogenesis (83) enhances the response to anti-PD-1 therapy in melanoma (84) and colorectal cancers (85, 86).